Healthcare / Pharmaceuticals·London, United Kingdom·Founded 2000

GSK sustainability score: 51/100

GlaxoSmithKline is a multinational pharmaceutical and biotechnology manufacturer headquartered in London, with operations spanning drug development, manufacturing, and vaccines.

Is this your business? Add your evidence →

51/100
Making progress+1 since last review
3rd of 19 in Healthcare / Pharmaceuticals
Pending reviewStrong evidence· 19 src

GSK has credible climate infrastructure: verified Scope 1&2 data, SBTi-validated net-zero to 2045, and sector-leading nature disclosures. But the company is tracking only 12% of its required 80% emissions cut by 2030. Supply chain data gaps, 49% waste circularity (vs 100% target), and trade association misalignment on EU climate policy expose the gap between commitment and delivery.

GSK scores 51/100 (Making progress) on SINK's independent climate assessment, scored from public data only. Fees pay for the review, never the result. Last verified October 2026.

That places GSK joint 126th of 847 companies scored, and 3rd of 19 in Healthcare / Pharmaceuticals.

At a glance

GSK's strongest and weakest areas

Strongest
  • Emissions from its own operations8/10
  • How clean its energy is8/10
Weakest
  • Whether its emissions are falling5/10
  • Emissions from its supply chain6/10
See all ten questions ↓
GSK in context

How does GSK compare with other healthcare / pharmaceuticals companies?

Where GSK sits among healthcare / pharmaceuticals peers.

Among the 19 major healthcare / pharmaceuticals brands we've scored, GSK sits 3rd of 19.

3/19
GSK's rank
44
Industry average
33
Industry low
53
Industry high
See all 19 in Healthcare / Pharmaceuticals →
What would raise this score

Where GSK lost the most points

Its three lowest-scoring questions, and what the evidence didn't show.

  1. Whether its emissions are falling5/10

    Target requires 80% absolute reduction by 2030; current trajectory is only ~12% in first three years—roughly half the required linear path.

  2. Emissions from its supply chain6/10

    2024 full category breakdown not yet released; categories shown as zero.

  3. How it uses materials and handles waste6/10

    Single-use plastics elimination merged into broader waste target; supply chain materials transparency incomplete.

A score changes when the evidence does. We use new published evidence at the next rescore. Evidence that isn't public can count through an evidence review.

For GSK

Is this your company?

  • Use this score in tenders

    Send the link, or the one-page score sheet. It links back to this page and every source. Free.

    Open the score sheet →
  • Add your evidence, £99

    Scored low because little is published? Send us your evidence. A person reviews it and your score reflects what you really do. Done within 5 working days.

    Evidence review →
  • Go tender-ready, £495 a year

    A yearly rescore, a check of up to 25 key suppliers and a score badge for your website (coming soon).

    Get in touch →
Fees pay for the review, never the result.
The ten questions

What is GSK doing well, and where does it fall short?

Strongest on Carbon Footprint — Operations and Energy Source (8/10, 8/10). Weakest on Emissions Trajectory and Carbon Footprint — Supply Chain (5/10, 6/10).

How this score has moved

Has GSK's score changed?

GSK's score has moved from 50 to 51 across 2 recorded reviews, up 1 point.

0255075100504 April 2026513 October 2026
  1. 50 → 51+13 October 2026

    Aggregator-citation sweep: broker citations replaced with the primary disclosures they mirror, re-scored through the guarded pipeline under pinned code 9196601.

  2. Scored 504 April 2026

    Initial score at platform launch

Method and evidence

How we worked this out

The formula and all 19 sources.

About GSK

GlaxoSmithKline is a multinational pharmaceutical and biotechnology manufacturer headquartered in London, with operations spanning drug development, manufacturing, and vaccines. It is one of the world's largest pharmaceutical companies by revenue, competing with Pfizer, Roche, and Novartis in primary care, oncology, and vaccines.

Founded
2000
Headquarters
London, United Kingdom
Employees
~99,300 (2016)
Annual revenue
~$40.1B
Company website ↗
THE SUNDAY RUNDOWN

Which companies moved this week, and why.

One email, every Sunday. Score changes, new research, the stories behind the numbers. Free.

No spam. Unsubscribe in one click.

Checking a company?

Search free →

Asked to prove you're sustainable?

Get your business scored, free →

Been scored?

See what's behind your number →

Fees pay for the review, never the result.